SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Danser, A. J.
Right arrow Articles by Nguyen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danser, A. J.
Right arrow Articles by Nguyen, G.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Spotlight on Renin

The Renin Academy Summit: advancing the understanding of renin science

AH Jan Danser

Department of Pharmacology, Erasmus MC, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands

Genevieve Nguyen

Institut de la Santé et de la Recherche Médicale (INSERM) Unit 833 and College de France, 11 place Marcelin Berthelot, 75005, Paris, France

References

  • Burcklé CA, Jan Danser AH, Müller DN et al. Elevated blood pressure and heart rate in human renin receptor transgenic rats. Hypertension 2006;47:552-6.[Abstract/Free Full Text]
  • Kaneshiro Y., Ichihara A., Sakoda M. et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007;18:1789-95.[Abstract/Free Full Text]
  • Nguyen G., Danser AH Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp Physiol 2008;93:557-63.[Abstract/Free Full Text]
  • Danser AH, van den Dorpel MA, Deinum J. et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-7.[Abstract/Free Full Text]
  • Danser AH, van Kesteren CA, Bax WA et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997;96:220-6.[Abstract/Free Full Text]
  • Deinum J., Rønn B., Mathiesen E. et al. Increase in serum prorenin precedes onset of microalbuminuria in patients prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia 1999;42:1006-10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Peters B., Grisk O., Becher B. et al. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 2008;26:102-09.[Web of Science][Medline] [Order article via Infotrieve]
  • Mercure C., Prescott G., Lacomabe M-J. et al. Chronic increases in circulating prorenin are not associated with renal or cardiac pathologies. JRAAS 2008;9(Suppl 1):S4. doi:10.3317/jraas.2008.010.
  • Derkx FH, Schalekamp MP, Schalekamp MA Two-step prorenin-renin conversion. Isolation of an intermediary form of activated prorenin. J Biol Chem 1987;262:2472-7.[Abstract/Free Full Text]
  • Mercure C., Thibault G., Lussier-Cacan S. et al. Molecular analysis of human prorenin prosegment variants in vitro and in vivo. J Biol Chem 1995;270:16355-9.[Abstract/Free Full Text]
  • Suzuki F., Hayakawa M., Nakagawa T. et al. Human prorenin has `gate and handle` regions for its nonproteolytic activation. J Biol Chem 2003;278:22217-22.[Abstract/Free Full Text]
  • Ichihara A., Hayashi M., Kaneshiro Y. et al. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the `handle` region for nonproteolytic activation of prorenin. J Clin Invest 2004;114:1128-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Uddin MN, Nabi AH, Nakagawa T. et al. Non-proteolytic activation of prorenin: activation by (pro)renin receptor and its inhibition by a prorenin prosegment, `decoy peptide`. Front Biosci 2008;13:745-53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Feldt S., Batenburg WW, Mazak I. et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008;51:682-8.[Abstract/Free Full Text]
  • Feldt S., Maschke U., Dechend R. et al. The putative (pro)renin receptor blocker HRP fails to prevent (pro)renin signaling. J Am Soc Nephrol 2008;19:743-8.[Abstract/Free Full Text]
  • Takahashi H., Ichihara A., Kaneshiro Y. et al. Regression of nephropathy developed in diabetes by (pro)renin receptor blockade. J Am Soc Nephrol 2007;18:2054-61.[Abstract/Free Full Text]
  • Satofuka S., Ichihara A., Nagai N. et al. Role of nonproteolytically activated prorenin in pathologic, but not physiologic, retinal neovascularization. Invest Ophthalmol Vis Sci 2007;48:422-9.[Abstract/Free Full Text]
  • Oh BH, Mitchell J., Herron JR et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63.[Abstract/Free Full Text]
  • Andersen K., Weinberger MH, Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26:589-99.[Web of Science][Medline] [Order article via Infotrieve]
  • Persson F., Rossing P., Schjoedt KJ et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008 Ma12 [Epub ahead of print].
  • Feldman DL, Persohn E., Schutz H. et al. Renal localisation of the renin inhibitor aliskiren. J Clin Hypertens 2006;8:A80-A81 (P-178).
  • Feldman DL, Jin L., Xuan H. et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008 [in press].
  • Müller DN, Luft FC Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221-8.[Abstract/Free Full Text]
  • Uresin Y., Taylor AA, Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. JRAAS 2007;8:190-8.[Medline] [Order article via Infotrieve]
  • Oparil S., Yarrows, S., Patel S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Parving H-H., Lewis JB, Lewis EJ, Hollenberg NK Aliskiren in the evaluation of proteinuria in diabetes (AVOID). Abstract and poster #SA-PO1051 presented at American Society of Nephrology Renal Week, San Francisco, USA. 3 November 2007.
  • McMurray JJV. Haemodynamic, neurohumoral, renal and ambulatory electrocardiographic effects of a new oral renin inhibitor in stable heart failure. Oral presentation at European Society of Cardiology Congress, Vienna, Austria. 1-5 September 2007.
  • Azizi M., Webb R., Nussberger J., Hollenberg NK Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56.[Web of Science][Medline] [Order article via Infotrieve]
  • Batenburg WW, de Bruin RJ, van Gool JM et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008;28:1151-7.[Abstract/Free Full Text]
  • Nussberger J., Aubert JF, Bouzourene K. et al. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008;51:1306-11.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 9, No. 2, 119-123 (2008)
DOI: 10.3317/jraas.2008.020


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Danser, A. J.
Right arrow Articles by Nguyen, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Danser, A. J.
Right arrow Articles by Nguyen, G.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement